Using Bevacizumab with Laser Treatment for Premature Infants' Eye Condition
Author Information
Author(s): Seemant Raizada, Jamal Al Kandari, Ahmad Al Bahar
Primary Institution: Al-Bahar Eye Centre, Ibn Sina Hospital, Kuwait
Hypothesis
Can intravitreal Bevacizumab combined with laser therapy effectively treat retinopathy of prematurity?
Conclusion
The study suggests that while Bevacizumab may reduce vascular activity in ROP, the evidence is not strong enough to justify its routine use.
Supporting Evidence
- Bevacizumab is known to decrease neovascular proliferation.
- The authors did not document the procedure for intravitreal injection, which is important for reproducibility.
- Intravitreal injections in neonates are complicated due to their unique eye anatomy.
- General anesthesia for neonates can lead to serious complications.
- Previous studies have shown that laser therapy can also reduce vascular activity.
Takeaway
Doctors are trying a new medicine called Bevacizumab to help babies with eye problems, but they need to be careful because it's not clear if it really works better than the usual treatment.
Methodology
This is a case series involving the simultaneous use of Bevacizumab and laser therapy in infants with ROP.
Potential Biases
There is a risk of bias due to the lack of a sham or control group for comparison.
Limitations
The study lacks a control group and clear inclusion criteria, making it difficult to assess the effectiveness of Bevacizumab alone.
Participant Demographics
The study involved 8 infants with stage 3 to stage 4 ROP.
Want to read the original?
Access the complete publication on the publisher's website